These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32696072)

  • 21. Detection of Wilms' tumor antigen--specific CTL in tumor-draining lymph nodes of patients with early breast cancer.
    Gillmore R; Xue SA; Holler A; Kaeda J; Hadjiminas D; Healy V; Dina R; Parry SC; Bellantuono I; Ghani Y; Coombes RC; Waxman J; Stauss HJ
    Clin Cancer Res; 2006 Jan; 12(1):34-42. PubMed ID: 16397021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602).
    Slingluff CL; Lee S; Zhao F; Chianese-Bullock KA; Olson WC; Butterfield LH; Whiteside TL; Leming PD; Kirkwood JM
    Clin Cancer Res; 2013 Aug; 19(15):4228-38. PubMed ID: 23653149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generation of Melan-A/MART-1-specific CD8+ cytotoxic T lymphocytes from human naive precursors: helper effect requirement for efficient primary cytotoxic T lymphocyte induction in vitro.
    Ostankovitch M; Le Gal FA; Connan F; Chassin D; Choppin J; Guillet JG
    Int J Cancer; 1997 Sep; 72(6):987-94. PubMed ID: 9378563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Establishment of a stable T lymphoma cell line transduced with HLA-A*24:02-restricted WT1-specific TCR genes and its application to antigen-specific immunomonitoring.
    Watanabe K; Toji S; Ohtake J; Nakano K; Satoh T; Kitamura H; Nishimura T
    Biomed Res; 2013 Feb; 34(1):41-50. PubMed ID: 23428979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma.
    Ciesielski MJ; Kozbor D; Castanaro CA; Barone TA; Fenstermaker RA
    Cancer Immunol Immunother; 2008 Dec; 57(12):1827-35. PubMed ID: 18438666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. WT1 as a novel target antigen for cancer immunotherapy.
    Oka Y; Tsuboi A; Elisseeva OA; Udaka K; Sugiyama H
    Curr Cancer Drug Targets; 2002 Mar; 2(1):45-54. PubMed ID: 12188920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.
    Tsuboi A; Hashimoto N; Fujiki F; Morimoto S; Kagawa N; Nakajima H; Hosen N; Nishida S; Nakata J; Morita S; Sakamoto J; Oji Y; Oka Y; Sugiyama H
    Cancer Immunol Immunother; 2019 Feb; 68(2):331-340. PubMed ID: 30430205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers.
    Oka Y; Tsuboi A; Kawakami M; Elisseeva OA; Nakajima H; Udaka K; Kawase I; Oji Y; Sugiyama H
    Curr Med Chem; 2006; 13(20):2345-52. PubMed ID: 16918359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens.
    Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S
    Immunol Lett; 2005 Jun; 99(1):85-93. PubMed ID: 15894116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells.
    Koesters R; Linnebacher M; Coy JF; Germann A; Schwitalle Y; Findeisen P; von Knebel Doeberitz M
    Int J Cancer; 2004 Apr; 109(3):385-92. PubMed ID: 14961577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors.
    Ossendorp F; Mengedé E; Camps M; Filius R; Melief CJ
    J Exp Med; 1998 Mar; 187(5):693-702. PubMed ID: 9480979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies.
    Rezvani K; Yong AS; Mielke S; Jafarpour B; Savani BN; Le RQ; Eniafe R; Musse L; Boss C; Kurlander R; Barrett AJ
    Haematologica; 2011 Mar; 96(3):432-40. PubMed ID: 21134985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generation of donor-derived Wilms tumor antigen 1-specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study.
    Ferulli F; Tanzi M; Turin I; Montini E; Rosti V; Acquafredda G; Lisini D; Compagno F; Boghen S; Licari A; Marseglia G; Zecca M; Montagna D
    Cytotherapy; 2019 Sep; 21(9):958-972. PubMed ID: 31279696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Helper T cell determinant peptide contributes to induction of cellular immune responses by peptide vaccines against hepatitis C virus.
    Hiranuma K; Tamaki S; Nishimura Y; Kusuki S; Isogawa M; Kim G; Kaito M; Kuribayashi K; Adachi Y; Yasutomi Y
    J Gen Virol; 1999 Jan; 80 ( Pt 1)():187-193. PubMed ID: 9934701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
    Bioley G; Guillaume P; Luescher I; Bhardwaj N; Mears G; Old L; Valmori D; Ayyoub M
    J Immunother; 2009; 32(2):161-8. PubMed ID: 19238015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
    Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles.
    Kobayashi H; Song Y; Hoon DS; Appella E; Celis E
    Cancer Res; 2001 Jun; 61(12):4773-8. PubMed ID: 11406551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses.
    Uttenthal B; Martinez-Davila I; Ivey A; Craddock C; Chen F; Virchis A; Kottaridis P; Grimwade D; Khwaja A; Stauss H; Morris EC
    Br J Haematol; 2014 Feb; 164(3):366-75. PubMed ID: 24422723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of mature dendritic cells pulsed with a novel WT1 helper peptide on the induction of HLA‑A2‑restricted WT1‑reactive CD8+ T cells.
    Kan S; Bito T; Shimabuku M; Taguchi J; Ohkusa T; Shimodaira S; Sugiyama H; Koido S
    Int J Oncol; 2020 Oct; 57(4):1047-1056. PubMed ID: 32945369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.